Do blood clots in the AstraZeneca and Johnson & Johnson COVID-19 vaccine related to gender and age of people?
Those most at risk at those in the 18 to 29 age group. However, the experts claim there are many other people at higher risk of blood clots. And women generally have a higher risk of cerebral venous sinus thrombosis. Moreover, oral contraceptives are associated with an increased risk of blood clotting including cerebral venous sinus thrombosis. Initially, the numbers seemed to suggest that cerebral venous sinus thrombosis cases occur more often in younger individuals and in females. Kindly check the following link:
https://www.express.co.uk/life-style/health/1420588/blood-clots-risk-AstraZeneca-covid-vaccine-news-aspirin-prevention-blood-clotting-EVG
A new clinical trial indicated that in numerous animal models vaccine donation with full-length spike protein predisposed to the inflammatory pulmonary disease complication. In addition, it has been hypothesized that spike protein-based vaccines could potentiate platelet activation and aggregation leading to thrombosis and blood clots by initiating autoantibodies against ACE2 of human platelets or triggering platelets aggregation through the strong interaction with their surface ACE2. A study found that SARS-CoV-2 Spike protein directly potentiates platelet activation, enhanced platelet aggregation. After incubation with spike protein, platelets also displayed markedly clot retraction. Kindly check the following links:
https://clinicaltrials.gov/ct2/show/NCT04730895
https://www.frontiersin.org/articles/10.3389/fimmu.2021.654507/abstract
I think that this may be due to the predisposition of the vessels and the blood itself to thrombosis. Maybe the blood group plays a role here, or vaccination does not give birth in time. Time and statistics can give answers, as well as analyzes.
Mechanism of clotting with Johnson & Johnson COVID-19 vaccine: Thrombotic Thrombocytopenia (TTP)
There is production of antibodies against platelet factor 4 (PF4)–heparin as the reason for TTP.
For details have a look at this letter from NEJM:
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination
https://www.nejm.org/doi/pdf/10.1056/NEJMc2105869?articleTools=true
Dear Manal Hadi Kanaan
Please check this article
Article Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination
Johnson & Johnson COVID-19 vaccination to be resumed soon in USA after a pause
Please have a look at this news report:
https://www.washingtonpost.com/health/2021/04/23/johnson-and-johnson-vaccine-blood-clots/
Reports of blood clots have doomed the future of AstraZeneca and Jhonson & Jhonson COVID-19 vaccines.